OBJECTIVES: End stage renal disease affects <1% of the Medicare population but accounts for ~7% of Medicare paid claimsDespite benefits of arteriovenous fistulas for vascular access for hemodialysis patients, reinterventions to maintain patency are common. A recent randomized controlled trial evaluated the safety and efficacy of the LUTONIX^{® METHODS: An economic model was developed from a U.S. payer perspective based on 12-month reintervention rates from the Lutonix AV trial. Reintervention costs were based on real-world CMS data for vascular access percutaneous interventions across settings. Payer procedure costs were based on reimbursement amounts for each site of service. The weighted average cost of a reintervention was estimated to be $4,724 based on the distribution of procedure types by setting. An incremental product acquisition cost (i.e., LUTONIX® RESULTS: The model predicted that LUTONIX®}